1. Prescribe to Prevent
  2. Module Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists Information Video CME Post-Test Evaluation
  1. Military Modules
  2. Module 1 Military SCOPE of Pain: Safe and Competent Opioid Prescribing For Providers Working with Veterans and Military Service Personnel Information Video CME Post-Test Evaluation
  3. Module 2 Military SCOPE of Pain: Safe and Competent Opioid Prescribing For Providers Working with Veterans and Military Service Personnel Information Video CME Post-Test Evaluation
  1. Video Modules
  2. Module 1 Case Studies In Practice: Applying Principles
    of Safe Opioid Prescribing
    Information Introduction Cases Case I Case II Case III Certification CME Post-Test Evaluation
  3. Module 2 Complex Convrs. High Dose Opioids
    & Illicit Drug Use
    Information Introduction Cases Case I-A Case I-B Case II Certification CME Post-Test Evaluation
  4. Module 3 Using the PDMP PMP Questionable Activity Information Introduction Cases Case I Case II Certification CME Post-Test Evaluation

For core clinical content designed to help you safely and effectively manage patients with chronic pain, when appropriate, with opioid analgesics, please visit our sister site, SCOPE of Pain.

  1. Supplemental Info Massachusetts PMP Panel Discussion Q & A Sessions

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and the Massachusetts Board of Registration in Medicine. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this enduring material for a maximum of 4.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program meets the criteria of the Massachusetts Board of Registration in Medicine for 4.75 hours of risk management study.

This program meets the criteria of the Massachusetts Board of Registration in Medicine for 4.75 hours of opioid education.

In order to receive credit, participants must view the content of each module and complete the post-test and evaluation for each. Participants who receive a grade of 70% or greater on the post-tests will receive credit. Modules can be completed individually (each module is designated for AMA PRA Category 1 Credit).

This activity was planned in collaboration with the Massachusetts Department of Public Health, the Massachusetts Hospital Association, and the Massachusetts Medical Society.


Target Audience
Physicians, nurse practitioners, physician assistants, dentists and pharmacists


Educational Objectives

VIDEO MODULES

In Practice:  Applying Principles of Safe Opioid Prescribing

  • Apply a practical framework for decision-making on the initiation, maintenance, and discontinuation of opioid analgesics for the treatment of chronic pain.

 

In Practice: Complex Conversations

  • Discuss treatment options when inheriting a patient on high-dose opioids.
  • Discuss communication strategies with patients on opioid therapy.

 

In Practice: Using the PDMP

  • Use the PDMP as a tool to discover questionable prescription opioid activity.
  • Communicate with patients to diagnose the cause of questionable activity and determine a course of action.


 

MILITARY SCOPE OF PAIN

Module 1

  • Discuss the breadth and quality of evidence for the use of opioids for chronic pain, including current gaps in knowledge.
  • Describe current treatment paradigms for treating patients with chronic pain.

 

Module 2

  • Describe the use of universal precautions when treating patients with chronic pain.
  • Apply appropriate communications strategies when initiating, managing, and, if necessary, terminating opioids for patients with chronic pain.


 

PRESCRIBE TO PREVENT

  • Explain the epidemiology of overdose
  • Explain the rational for and scope of overdose prevention education and naloxone rescue kit distribution
  • Incorporate overdose prevention education and naloxone rescue kits into medical and pharmacy practice by educating patients about overdose risk reduction and furnishing naloxone rescue kits
  • Explain the legal and policy environment regarding furnishing naloxone rescue kits


Date of Original Release: February 1, 2011
Date of Most Recent Review:  January 31, 2014
Date of Expiration: January 31, 2015

For questions about CME, please contact cme@bu.edu or www.bu.edu/cme.
To view Boston University's Privacy Policy, please see http://www.bumc.bu.edu/cme/policies/.


Disclosure Policy
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty
Daniel P. Alford, MD, MPH, FACP (Course Director)
Associate Professor of Medicine
Boston University School of Medicine
Boston Medical Center
Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that he does not discuss unlabeled/investigational uses of a commercial product.

Sheila Chapman, MD
Assistant Professor of Medicine
Boston Medical Center
Boston University School of Medicine
Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that he does not discuss unlabeled/investigational uses of a commercial product.

Jane Liebschutz, MD, MPH, FACP
Associate Professor of Medicine and Social and Behavioral Sciences
Boston University Schools of Medicine and Public Health
Boston Medical Center
Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that she does not discuss unlabeled/investigational uses of a commercial product.

Karen H. Seal, MD, MPH
San Francisco VA Medical Center and the University of California, San Francisco
Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that she does not plan to discuss unlabeled/investigational uses of a commercial product.

Emily Sachs, PhD
San Francisco VA Medical Center and the University of California, San Francisco
Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that she does not plan to discuss unlabeled/investigational uses of a commercial product.

Tracy Lin, PharmD
San Francisco VA Medical Center and the University of California, San Francisco
Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that she does not plan to discuss unlabeled/investigational uses of a commercial product.

Alexander Y. Walley, MD, MSc (Course Co-Director)
Assistant Professor of Medicine
Co-Program Director, Addiction Medicine Fellowship Program Program
Director, Fellow Immersion Training Program
Boston University School of Medicine and Boston Medical Center
Faculty member is a consultant for Social Sciences Innovation Research, Inc. Faculty member indicates that he does plan to discuss unlabeled/investigational uses of a commercial product.  The intra-nasal delivery of naloxone is not approved by the FDA.

Donna Beers BSN, RN-BC, CARN
Nurse Manager
TOPCARE Project
Boston Medical Center
Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that he does not plan to discuss unlabeled/investigational uses of a commercial product.

Jeffrey Bratberg, PharmD, BCPS
Clinical Professor of Pharmacy
University of Rhode Island College of Pharmacy
Infectious Disease Specialist
Roger Williams Medical Center, Providence, RI
Faculty member is a consultant for and on the speakers bureau for Merck, and on the speakers bureau for Sanofi Pasteur. Faculty member indicates that he does plan to discuss unlabeled/ investigational uses of a commercial product.  The intra-nasal delivery of naloxone is not approved by the FDA.

Corey Davis, JD, MSPH
Deputy Director
The Network for Public Health Law
Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that he does plan to discuss unlabeled/investigational uses of a commercial product.  The intra-nasal delivery of naloxone is not approved by the FDA.

Traci Green, MD, Video Actor, is employed by Inflexxion, Inc.; Nkiruka Emeagwali, MD, Video Actor, has nothing to disclose with regards to commercial support.  They do discuss unlabeled/investigational uses of a commercial product.  The intra-nasal delivery of naloxone is not approved by the FDA.

Ilana Hardesty, Program Operations Manager, Boston University School of Medicine CME Office, Patti-Ann Collins, Lead Nurse Planner, and Jason Worcester, MD, Boston University School of Medicine, have nothing to disclose with regards to commercial support.
 

Disclaimer

THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.

This web-based activity is supported by funding from the Massachusetts Board of Registration in Medicine, and by an unrestricted educational grant from the Substance Abuse and Mental Health Services Administration of the U.S. Department of Health and Human Services.

The development of content for the live meetings was supported by unrestricted educational grants from Purdue Pharma L.P. and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Viewing/Usability Requirements

To view our videos, you will need to have javascript enabled and also have Adobe Flash Player Version 9.0 or greater installed.
This site is optimized for all modern browsers and operating systems, including Internet Explorer 7+, Safari 4+, and Firefox 3+.

Please register using the form below to participate in the CME Opioid Prescribing Program.

Before completing the registration, please read our Accreditation Information. You will need to then check below that you have indeed read and agree to these terms.

Notes on Registration:
Password: Must consist of [ 6 ] to [ 20 ] characters consisting of only numbers and/or letters.

Account Information

*
*
* Please type your degree/credentials as you would like it to appear on the certificate.
* Please indicate what type of provider you are.
*
*
*
*
*
*
Ex. Format: 000-111-2222
Ex. Format: 000-111-2222

User Information

If you do not choose, your email will be your designated username.
* Must be 6 to 20 characters. Only numbers and/or letters.
* Please confirm your chosen password.
*
* Please confirm your email address.

Confirmation

* Select "I've Read & Agree" to confirm your registration.
* Type the RED letters (seen below) to confirm (case-sensitive).
Finish & Submit